FOR IMMEDIATE RELEASE (Calgary, Alberta, January 28, 2014) – Zephyr Sleep Technologies Inc. (Zephyr), a leader in the development of scientifically validated sleep systems, is pleased to announce that Health Canada has approved MATRx for immediate sale in Canada. MATRx is a leading-edge, remote-controlled titration study that enables physicians to confidently prescribe oral appliance therapy (OAT) and effectively treat obstructive sleep apnea (OSA).

MATRx’s highly accurate, patented technology is used during polysomnography (PSG) in hospitals and private sleep centers. The MATRx lab system can accurately select which OSA patients will respond to an oral appliance. In addition, the MATRx test also provides the therapeutic target protrusive position allowing for effective treatment with oral appliance therapy. MATRx is an FDA cleared medical device currently installed in over 60 sleep centers in the United States and is now available in Canada. MATRx is the only medical device that, in a single night, produces test results that are trusted by sleep physicians and dentists to treat thousands of OSA patients with OAT.

MATRx will be exclusively sold and distributed in Canada by Respiratory Homecare Solutions (RHS). RHS is a privately held medical services company that designs comprehensive patient centered programs and offers products that effectively treat respiratory and sleep apnea conditions. RHS has an experienced and knowledgeable national sales force, making their organization the ideal partner to launch MATRx in Canada. Through RHS, Zephyr will have authorized sales representatives and customer support teams located throughout Canada who can provide information about MATRx.

“The MATRx system uses unprecedented technology and is only available through Zephyr Sleep Technologies and our distribution partners. We are very pleased to finally be able to offer this new and exciting technology to Canada. Our Canadian partner, Respiratory Homecare Solutions, is ready to go and we expect MATRx to be an absolute success in Canada” says CEO, Paul Cataford.

OSA patient compliance with continuous positive airway pressure (CPAP) continues to be a challenge. OAT is an alternative treatment and is generally preferred by OSA patients. Patient preference for OAT translates to higher compliance rates and provides an equivalent health outcome to CPAP. MATRx empowers patients to make an informed choice to pursue OAT to successfully treat their OSA. Patients are, at an increasing rate, requesting they be treated with oral appliance therapy and a MATRx test determines, with 100% confidence, if an oral appliance will treat their illness. The MATRx technology is the gateway to patient centered management of OSA and changes how the disease will be treated in the future.

“Our experience in the US shows that many sleep dentists are now demanding a MATRx test before fitting a patient with OAT. After completing a MATRx test, we now know whether a patient is suitable for OAT and we know the target therapeutic position. The sleep dentist’s job is easier and more effective resulting in higher patient satisfaction, reduced chair time and faster time to treatment” says Dr. Shouresh Charkhandeh, Zephyr’s Chief Dental Officer.

Now with the Health Canada approval of MATRx and the current US distribution of this sleep system, Zephyr is able to help sleep centers in North America reach a new segment of patients, improving their long-term treatment compliance and therapeutic outcomes with oral appliance therapy. Zephyr is excited that MATRx can assist sleep physicians and dentists deliver effective patient centered care while also generating incremental revenue for their business.

The MATRx system is a clinically validated technology with its manuscript recently published in the October 2013 issue of the Journal SLEEP. “The SLEEP article led to increased demand for MATRx in the US and a flood of enquiries from Canada; MATRx is very valuable to the sleep medicine community so we are thrilled that the technology is now available to Canadian sleep centers” says Mark Durston, Zephyr’s Director of Sales and Distribution.

The launch of MATRx in Canada will offer a significant positive change for the future of oral appliance therapy. Now Canadian physicians will confidently prescribe oral appliance therapy and collaborate with dentists to achieve efficacious treatment for the Canadian OSA patient.


Zephyr Sleep Technologies is a privately held medical device company that develops, manufactures and sells innovative, scientifically-validated medical devices to improve sleep. Zephyr works with sleep labs, technicians, physicians, dentists and leading edge sleep researchers to improve the treatment for obstructive sleep apnea. MATRx was developed by Zephyr and is based on and powered by the proprietary and patented technology known as OATRx. Zephyr is based in Calgary, Alberta. Please visit zephyrsleep.com


Respiratory Homecare Solutions is a privately held medical services company that designs and integrates efficient, comprehensive programs, products and services for the cardio-respiratory community. RHS’s success is measured by the satisfaction of those with whom they partner, those they employ and those they have the privilege to serve. Please visit www.rhscanada.com.


Canadian Sales
Rodney Rousseau, RRT, RPSGT, RST Co-President, Respiratory Homecare Solutions rod@rhscanada.com

U.S. Sales and Marketing
Mark Durston
Director of Sales and Distribution, Zephyr Sleep Technologies mdurston@zephyrsleep.com

RHS Marketing
Greg Stirrett
Vice President of Sales and Marketing, Respiratory Homecare Solutions greg@rhscanada.com

“We are pleased to finally market and sell MATRx in Canada. Zephyr and RHS have been planning the Canadian product release of MATRx over the past few months. We have customers who had already contacted us because they were anxiously awaiting Health Canada approval so they could immediately install MATRx in their sleep centers” states Rodney Rousseau, RHS’s Co-President.


Related Articles

Image MATRx End of Life Notice

Dear valued MATRx customer, The MATRx in-lab was cleared by the Food and Drug Administration (FDA) in March, 2012 and was released in the ...

Read more